# New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

> **NCT07110662** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 9 (estimated)

## Conditions studied

- Toxic Epidermal Necrolysis
- Immunotherapy
- Cutaneous Adverse Drug Reactions (CADR)

## Interventions

- **DRUG:** DARATUMUMAB (DARZALEX®)

## Key facts

- **NCT ID:** NCT07110662
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2028-10-29
- **Final completion:** 2029-04-29
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110662, "New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07110662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*